Key Points:
- Amanta Healthcare IPO oversubscribed 82x; strong demand from all investor categories.
- Grey market premium signals optimism ahead of September 9 listing.
- IPO proceeds to fund manufacturing expansion and boost pharma capacity.
Pharmaceutical company’s issue sees overwhelming demand across investor categories ahead of September 9 listing
Amanta Healthcare’s Initial Public Offering (IPO) drew overwhelming interest from investors, with the issue subscribed 82.61 times by the close of bidding on September 3, 2025. The allotment of shares is expected to be finalized on September 4, giving applicants clarity on whether they have secured shares in the heavily oversubscribed issue.
The IPO offered 7 million shares but received bids for 578.28 million, according to data from the National Stock Exchange (NSE). The strongest demand came from Non-Institutional Investors (NIIs), whose quota was subscribed 209.42 times. Retail investors also showed robust participation at 54.98 times, while Qualified Institutional Buyers (QIBs) subscribed 35.86 times.
Investors awaiting allotment can check their status on the official websites of the NSE, BSE, and MUFG Intime India, the registrar of the issue. Applicants will need details such as their Application Number, Permanent Account Number (PAN), or Client ID to access the results once the allotment is finalized. Refunds and credit of shares to successful applicants’ Demat accounts are expected by September 5.
Grey Market Premium Indicates Optimism
Amanta Healthcare’s shares are already showing momentum in the grey market. According to sources tracking unlisted trading activity, the company’s shares were commanding a premium of ₹8.5, placing the grey market price at ₹134.5. This translates to a 6.75 percent premium over the upper price band of ₹126.
While grey market trends do not guarantee performance on listing day, the early premium signals optimism among traders about the stock’s market debut. With the issue priced between ₹120 and ₹126 per share, the response indicates investor confidence in both the company’s fundamentals and growth plans.
Listing Date and Market Debut
Shares of Amanta Healthcare are scheduled to list on both the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) on September 9, 2025. Market watchers expect significant activity on debut day given the high oversubscription and strong grey market interest.
The Initial Public Offering (IPO) opened for subscription on September 1 and closed on September 3. Following allotment finalization and refunds, trading is anticipated to begin on schedule, barring unforeseen regulatory delays.
Planned Use of Funds and Expansion Strategy
According to the company’s red herring prospectus, the proceeds of the IPO will be used to expand manufacturing capacity. The largest portion is earmarked for setting up a new manufacturing line of SteriPort and Small Volume Parenterals (SVP) at Hariyala in Kheda, Gujarat. Funds will also support civil construction, acquisition of plant and machinery, and other equipment necessary for scaling up operations.
The company has also allocated part of the proceeds for general corporate purposes, which may include working capital requirements and business development initiatives. Beeline Capital Advisors is serving as the sole book-running lead manager for the issue.
Industry Position and Investor Outlook
Amanta Healthcare specializes in sterile injectable products, a segment of the pharmaceutical industry experiencing consistent demand due to growing healthcare needs globally. With India emerging as a key hub for pharmaceutical manufacturing, the company’s expansion plans are seen as timely.
Analysts suggest that the robust subscription numbers highlight both retail and institutional investors’ confidence in the company’s future prospects. However, market experts also caution that oversubscription levels and grey market premiums, while encouraging, do not always reflect long-term stock performance.
As the company prepares for its stock market debut, attention will remain on how the shares perform on listing day and whether demand sustains beyond the initial surge. The IPO marks an important step in Amanta Healthcare’s growth trajectory, positioning it to increase production capacity and enhance competitiveness in the pharmaceutical manufacturing sector.
Visit Business Viewpoint Magazine for the most recent information.
